Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
MERCK SHARP & DOHME (NEW ZEALAND) LIMITED,Pembrolizumab,Pembrolizumab in combination with chemotherapy for those with recurrent or metastatic head and neck squamous cell carcinoma irrespective of Combined Positive Score (ie. an all-comers population),Pembrolizumab (KEYTRUDA (for HNSCC)),Recommended for decline,Hospital,
